The past years have also seen increased community acceptance of the idea that public and private sectors can collaborate pre-competitively in areas that were once considered commercially sensitive. The "open-access, open-source, open-data" paradigm is now accepted as an accelerator of biomedical science. Critically, this paradigm has expanded to include the notion that placing chemical matter, including advanced molecules such as chemical probes, in the public domain without complex and rate-limiting intellectual property agreements provides immense scientific value .